Targeted Combination Therapy for Glioblastoma by Co-Delivery of Doxorubicin, YAP-siRNA and Gold Nanorods

The combination of brain targeting drug delivery systems and multi-modal intervention pose a promising therapeutic approach for glioblastoma therapy. In this study, we developed an angiopep-2 peptide modified cationic liposomes loaded with doxorubicin, YAP-siRNA and gold nanorods (D/R@Ang2-Lip+Au) simultaneously, which has been characterized by high encapsulating efficiency for doxorubicin (95.4%) and effective binding of siRNA at N/P ratio of 20:1. The fluorescence imaging and flow cytometry analysis revealed high cellular uptake of D/R@Ang2-Lip+Au. Real-time quantitative polymerase chain reaction and western blot analysis indicated that D/R@Ang2-Lip+Au could effectively inhibit the expression of YAP protein. In vitro and in vivo studies showed that D/R@Ang2-Lip+Au had the ability to target glioma cells, and achieved better anti-proliferative effects compared with non-targeted D/R@Lip+Au. Moreover, in vivo experiment demonstrated that D/R@Ang2-Lip+Au was able to cross the blood-brain barrier, and combination therapy could significantly inhibit tumor growth. Therefore, the multifunctional D/R@Ang2-Lip+Au might provide a novel approach for effectively delivery of DOX, AuNRs and siRNA into the glioblastoma cells simultaneously and exerting synergistic therapeutic effects.